EP0150186A1 - Composition having an improved pharmaceutical activity and utilisation thereof in veterinary medecine - Google Patents

Composition having an improved pharmaceutical activity and utilisation thereof in veterinary medecine

Info

Publication number
EP0150186A1
EP0150186A1 EP84901729A EP84901729A EP0150186A1 EP 0150186 A1 EP0150186 A1 EP 0150186A1 EP 84901729 A EP84901729 A EP 84901729A EP 84901729 A EP84901729 A EP 84901729A EP 0150186 A1 EP0150186 A1 EP 0150186A1
Authority
EP
European Patent Office
Prior art keywords
antibiotic
composition
oxytetracycline
benzylpenicillin
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP84901729A
Other languages
German (de)
French (fr)
Inventor
André SPEECKE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ssm International Chemical Co Ltd
Original Assignee
Ssm International Chemical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ssm International Chemical Co Ltd filed Critical Ssm International Chemical Co Ltd
Publication of EP0150186A1 publication Critical patent/EP0150186A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Definitions

  • the present invention relates to an antibiotic composition
  • an antibiotic composition comprising, in an injectable form, a synergistic mixture of an antibiotic of the oxytetracycline type and of an antibiotic of the benzylpenlcillin type in order to combat certain diseases due to bacteria.
  • antibiotics are currently widely used for the treatment of mammals, in particular in veterinary medicine.
  • PFIZER Belgian Patent No. 505,709
  • antibiotic compositions containing simultaneously an antibiotic of the oxytetracycline or terramycin type and an antibiotic of the penicillin type are surprisingly effective against many different types of bacteria, in particular against various infectious microorganisms of the Salmonella and Pseudomonas groups, when used individually, these have only a low therapeutic value with respect to said microorganisms.
  • diseases caused by Salmonella there may be mentioned for humans, paratyphoid fever, salmonellosis septicemia, salmonellous enterocolitis, pneumonia and osteomyelitis.
  • Certain bacteria from the Salmonella group are also the cause of dangerous diseases in animals, such as infection due to Salmonella pullorum in poultry.
  • the present invention is also based on obtaining a surprising synergy of the two above-mentioned antibiotics.
  • an antibiotic composition comprising, in an injectable form, a synergistic mixture of an antibiotic of the oxytetracycline type and of an antibiotic of the benzylpenicillin type in order to combat certain diseases due to bacteria, essentially characterized in that it comprises, in addition to the two above-mentioned antibiotics, also an antibiotic of the Miltimycin type in an oxytetracycline: benzylpenicillin: Multimycin weight ratio comprised in a range varying from 10 to 30, preferably 20 of the first compound, 90 to 70, preferably 80 of the second compound and 1 to 15, preferably 7 of the third compound.
  • the synergistic composition of the invention finds its preferred veterinary application, given its effectiveness, in combating all infections of the mucous membranes, in particular mycoses caused by fungi and all necrotic diseases, for example necrosis, lingual necrobacillosis of the calves and canker.
  • Another field of application is the treatment of peritonitis, metritis, infectious pneumonia in foals (coryne bacteria flu) and the "white bad in cattle” (ulcers on the hooves) or panaris.
  • a galenical form of the antibiotic composition according to the invention was prepared by mixing the following constituents for 100 ml:
  • the mixing is carried out first by mixing together the compounds 1 / and 2 / then adding the compound 3 / thereafter, after which all the compounds listed under 4 / and 5 / are added thereto.
  • the preparation in liquid form at the dosages indicated above is injected at the rate of 20 ml per 100 kg of body weight into calves, the blood count being able to go up to 50 ml per head of adult cattle.
  • This dosage represents 6.25 million IU of antibiotics for 20 ml.
  • composition described has been found to be particularly effective in combating infections of the mucous membranes, in particular mycoses caused by fungi which, in many cases would have, in the absence of treatment with the synergistic composition of the invention, required cattle slaughter or surgical procedures. A young animal severely affected by Lingual necrobacillosis who refused to drink was cured within 24 hours.
  • composition has also been found to be very effective in the treatment of the other conditions mentioned above, while the use of the antibiotics mentioned in isolation has practically no effect.
  • the invention covers all the synergistic compositions of the invention with the supports, diluents and excipients usually used in pharmacology.
  • the invention extends to all these variants of application, composition or preparation.
  • An antibiotic composition comprising simultaneously oxytetracyclin, procain benzylpenicillin and colistin sulphate has a combined synergy activity susceptible to cure necrotic diseases and mucosa troubles for which no efficient remedy has been found heretofore.
  • An antibiotic composition comprising simultaneously oxytetracycline, procaine benzylpenicillin and colistin sulfate exerts a combined synergistic action capable of curing necrotic diseases and affections of the mucous membranes for which there are no valid remedies to date.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Une composition antibiotique comprenant simultanément de l'oxytétracycline, de la procaine benzylpénicilline et du sulfate de colistine exerce une action combinée synergique susceptible de guérir les maladies nécrotiques et les affections des muqueuses pour lesquelles il n'existe pas à ce jour de remèdes valables.An antibiotic composition comprising simultaneously oxytetracycline, procaine benzylpenicillin and colistin sulfate exerts a combined synergistic action capable of curing necrotic diseases and affections of the mucous membranes for which there are no valid remedies to date.

Description

COMPOSITION A ACTIVITE PHARMACEUTIQUE AMELIOREE ET UTILISATION DE CELLE-CI POUR DES USAGES VETERINAIRES.COMPOSITION WITH IMPROVED PHARMACEUTICAL ACTIVITY AND USE THEREOF FOR VETERINARY USES.
La présente invention est relative à une composition antibiotique comprenant, sous une forme injectable, un mélange synergique d'un antibiotique du type oxytetracycline et d'un antibiotique du type benzylpénlcilline en vue de combattre certaines maladies dues à des bactéries.The present invention relates to an antibiotic composition comprising, in an injectable form, a synergistic mixture of an antibiotic of the oxytetracycline type and of an antibiotic of the benzylpenlcillin type in order to combat certain diseases due to bacteria.
L'usage des antibiotiques s'est largement répandu et un grand nombre d'antibiotiques différents à effet spécifique particulier ou à large spectre d'action sont actuellement disponibles sur le marché.The use of antibiotics has spread widely and a large number of different antibiotics with a specific specific effect or with a broad spectrum of action are currently available on the market.
Ces antibiotiques sont actuellement largement utilisés pour le traitement de mammifères, notamment en médecine vétérinaire.These antibiotics are currently widely used for the treatment of mammals, in particular in veterinary medicine.
Pour diverses raisons, on s'aperçoit qu'un grand nombre de produits ne peuvent pas combattre certaines affections, en particulier des maladies infectieuses ou encore qu'ils perdent leur efficacité, vraisemblablement par suite de modifications des souches microbiennes, virales ou cryptogamiques.For various reasons, we realize that a large number of products cannot fight certain ailments, in particular infectious diseases, or that they lose their effectiveness, probably as a result of changes in microbial, viral or cryptogamic strains.
On sait par le brevet belge No 505.709 (PFIZER) que des compositions antibiotiques contenant simultanément un antibiotique du type oxytetracycline ou terramycine et un antibiotique du type pénicilline sont étonnamment efficaces contre maints types différents de bactéries, en particulier contre divers microorganismes infectieux des groupes Salmonella et Pseudomonas, alors qu'employés individuellement ceux-ci n'ont qu'une faible valeur thérapeutique vis-à-vis desdits microorganismes. Parmi les maladies causées par les Salmonella, on peut citer pour l'homme, la fièvre paratypholde, la septicémie salmonellique, l'entérocolite salmonellique, la pneumonie et l'ostéomyélite. Certaines bactéries du groupe des Salmonella sont aussi la cause de maladies dangereuses chez les animaux, telle l'infection due au Salmonella pullorum de la volaille.It is known from Belgian Patent No. 505,709 (PFIZER) that antibiotic compositions containing simultaneously an antibiotic of the oxytetracycline or terramycin type and an antibiotic of the penicillin type are surprisingly effective against many different types of bacteria, in particular against various infectious microorganisms of the Salmonella and Pseudomonas groups, when used individually, these have only a low therapeutic value with respect to said microorganisms. Among the diseases caused by Salmonella, there may be mentioned for humans, paratyphoid fever, salmonellosis septicemia, salmonellous enterocolitis, pneumonia and osteomyelitis. Certain bacteria from the Salmonella group are also the cause of dangerous diseases in animals, such as infection due to Salmonella pullorum in poultry.
La présente invention est également basée sur l'obtention d'une synergie surprenante des deux antibiotiques susdits.The present invention is also based on obtaining a surprising synergy of the two above-mentioned antibiotics.
Elle est basée sur la découverte que l'adjonction de sulfate de colistine ou Multimycine à un mélange des deux antibiotiques susdits élargit, de façon remarquable, les spectres d'applicabilité de la composition et fournit une composition susceptible de guérir des affections pour lesquelles il n'existe pas à ce jour de remèdes . valables.It is based on the discovery that the addition of colistin sulfate or Multimycin to a mixture of the two above-mentioned antibiotics widens, remarkably, the applicability spectra of the composition and provides a composition capable of curing conditions for which it does not exist. there are no remedies to date. valid.
Elle est relative à une composition antibiotique comprenant, sous une forme Injectable, un mélange synergique d'un antibiotique du type oxytetracycline et d'un antibiotique du type benzylpénicilline en vue de combattre certaines maladies dues à des bactéries, essentiellement caractérisée en ce qu'elle comporte, outre les deux antibiotiques susdits, également un antibiotique du type Miltimycine dans un rapport pondéral oxytetracycline : benzylpénicilline : Multimycine compris dans une plage variant de 10 à 30, de préférence 20 du premier composé, 90 à 70, de préférence 80 du deuxième composé et 1 à 15, de préférence 7 du troisième composé.It relates to an antibiotic composition comprising, in an injectable form, a synergistic mixture of an antibiotic of the oxytetracycline type and of an antibiotic of the benzylpenicillin type in order to combat certain diseases due to bacteria, essentially characterized in that it comprises, in addition to the two above-mentioned antibiotics, also an antibiotic of the Miltimycin type in an oxytetracycline: benzylpenicillin: Multimycin weight ratio comprised in a range varying from 10 to 30, preferably 20 of the first compound, 90 to 70, preferably 80 of the second compound and 1 to 15, preferably 7 of the third compound.
La composition synergique de l'invention trouve son application vétérinaire préférée, compte tenu de son efficacité, pour combattre toutes les infections des muqueuses, en particulier les mycoses provoquées par des champignons et toutes les maladies nécrotiques, par exemple la nécrose, la nécrobacillose linguale des veaux et le chancre.The synergistic composition of the invention finds its preferred veterinary application, given its effectiveness, in combating all infections of the mucous membranes, in particular mycoses caused by fungi and all necrotic diseases, for example necrosis, lingual necrobacillosis of the calves and canker.
Un autre champ d'application est constitué par le traitement de la péritonite, de la métrite, de la pneumonie infectieuse des poulains (coryne bactériesgrippe) et le ''blanc mal chez les bovins'' (ulcères sur les sabots) ou panaris.Another field of application is the treatment of peritonitis, metritis, infectious pneumonia in foals (coryne bacteria flu) and the "white bad in cattle" (ulcers on the hooves) or panaris.
Ces champs d'applications ne sont cependant pas limitatifs, car d'autres affections du même genre peuvent être traitées efficacement à l'aide de la composition de l'invention.These fields of application are not, however, limiting, since other affections of the same kind can be effectively treated using the composition of the invention.
L'invention sera décrite plus en détail à l'aide d'un exemple destiné à illustrer son caractère nouveau et inventif, sans que cependant ni la composition précise ni la forme galenique ne doivent: è tre considérées comme une limitation.The invention will be described in more detail with the aid of an example intended to illustrate its new and inventive character, without however that neither the precise composition nor the galenical form should: be considered as a limitation.
On a préparé une forme galenique de la composition antibiotique suivant l'invention en mélangeant pour 100 ml les constituants suivants :A galenical form of the antibiotic composition according to the invention was prepared by mixing the following constituents for 100 ml:
1/ Oxytetracycline HCl 926 mg1 / Oxytetracycline HCl 926 mg
2/ Procalne Benzylpénicilline 24000mg2 / Procalne Benzylpenicillin 24000mg
3/ Sulfate de colistine 10à100 mg3 / Colistin sulfate 10 to 100 mg
4/ Polyvidone constituant du solvant Aqua distillata ad 1 ml 5/ Magnes, formaldehyd bisulfis. 7 mg Magnesium Oxydum 7 mg Methylis paraoxybenzoas 0,68 mg Natri citras. (Vitamine A) 3,5 mg Natri carboxymethyl cellulos. diluant Propyll para hydroxybenzoas 0,12 mg Polyvinyl pyrrolid. diluant4 / Polyvidone constituting the solvent Aqua distillata ad 1 ml 5 / Magnes, formaldehyd bisulfis. 7 mg Magnesium Oxydum 7 mg Methylis paraoxybenzoas 0.68 mg Natri citras. (Vitamin A) 3.5 mg Natri carboxymethyl cellulos. diluent Propyll para hydroxybenzoas 0.12 mg Polyvinyl pyrrolid. diluent
6/ Propyleneglycol 12mg en tant que solvant6 / Propyleneglycol 12mg as solvent
Le mélange est réalisé d'abord en mélangeant entre eux les composés 1/ et 2/ ensuite en y ajoutant le composé 3/, après quoi tous les composés repris sous 4/ et 5/ y sont ajoutés.The mixing is carried out first by mixing together the compounds 1 / and 2 / then adding the compound 3 / thereafter, after which all the compounds listed under 4 / and 5 / are added thereto.
La préparation sous forme liquide aux dosages indiqués ci-dessus est injectée à raison de 20 ml par 100 kg de poids corporel à des veaux, le ciosage pouvant aller jusqu'à 50 ml par tête de bétail adulte.The preparation in liquid form at the dosages indicated above is injected at the rate of 20 ml per 100 kg of body weight into calves, the blood count being able to go up to 50 ml per head of adult cattle.
Ce dosage représente pour 20 ml, 6,25 millions d'UI d'antibiotiques.This dosage represents 6.25 million IU of antibiotics for 20 ml.
La composition décrite s'est révélée particulièrement efficace pour combattre les infections des muqueuses en particulier les mycoses provoquées par des champignons qui, dans de nombreux cas auraient en l'absence du traitement à l'aide de la composition synergique de l'invention,nécessité l'abattage du bétail ou des interventions chirurgicales. Une jeune bête fortement atteinte de nécrobacillose linguale et qui refusait de boire, a pu être guérie endéans les 24 heures.The composition described has been found to be particularly effective in combating infections of the mucous membranes, in particular mycoses caused by fungi which, in many cases would have, in the absence of treatment with the synergistic composition of the invention, required cattle slaughter or surgical procedures. A young animal severely affected by Lingual necrobacillosis who refused to drink was cured within 24 hours.
La composition s'est révélée également très efficace pour le traitement des autres affections signalées ci-dessus, alors que l'utilisation des antibiotiques cités isolément ne présente pratiquement pas d'effet.The composition has also been found to be very effective in the treatment of the other conditions mentioned above, while the use of the antibiotics mentioned in isolation has practically no effect.
Il convient de noter qu'en variante, il est possible d'ajouter au mélange synergique décrit d'autres antibiotiques bien que ceux-ci, pour la plupart des composés connus, ne semblent pas accroître l'efficacité de la composition synergique de l'invention.It should be noted that, as a variant, it is possible to add to the synergistic mixture described other antibiotics although these, for most of the known compounds, do not seem to increase the effectiveness of the synergistic composition of the invention.
Il doit être bien entendu que de nombreuses modifications peuvent être apportées à la forme d'exécution de l'invention qui a été décrite et que l'homme de métier notamment peut apporter de nombreuses variantes dans le choix notamment des excipients, supports ou diluants. En principe donc, l'invention couvre toutes les compositions synergiques de l'invention avec les supports, diluants et excipients utilisés habituellement en pharmacologie.It should be understood that many modifications can be made to the embodiment of the invention which has been described and that the skilled person in particular can make many variants in the choice in particular of excipients, carriers or diluents. In principle therefore, the invention covers all the synergistic compositions of the invention with the supports, diluents and excipients usually used in pharmacology.
Il convien" de noter que la plage d'application mentionnée est donnée à titre d'exemple et n'est nullement limitative. De même, la posologie particulière à chaque espèce peut être variée et les préparations de l'invention trouvent leur application aussi bien à titre préventif qu'à titre curatif, dans des interventions chirurgicales, etc.It should be noted that the range of application mentioned is given by way of example and is in no way limiting. Similarly, the dosage specific to each species can be varied and the preparations of the invention find their application as well preventively than curatively, in surgical procedures, etc.
L'invention s'étend à toutes ces variantes d'application, de composition ou de préparation. The invention extends to all these variants of application, composition or preparation.
u r rpe. -sw i n.i lP er raTirfï i iioiπ n. Jiu r rpe. -sw i n.i lP er raTirfï i iioiπ n. Ji
DEMANDE INTERNATIONALE PUBLIEE EN VERTU DU TRAITE DE COOPERATION EN MATIERE DE BREVETS ( PCT)INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)
(51) Classification internationale des brevets^ : (11) Numéro de publication internationale : WO 84/ 04249(51) International Patent Classification ^: (11) International publication number: WO 84/04249
A61K 37/02, 31/65 // (A61 K 37/02 A3 A61 K 31/65, 31/43) (43) Date de publication internationale:A61K 37/02, 31/65 // (A61 K 37/02 A3 A61 K 31/65, 31/43) (43) Date of international publication:
8 novembre 1984 (08.1 1.84)November 8, 1984 (08.1 1.84)
(21) Numéro de la demande internationale: PCT/BE84/00012 (81) Etats désignés: AT (brevet européen), BE (brevet euro- ι péen), CH (brevet européen), DE (brevet européen), ](21) International application number: PCT / BE84 / 00012 (81) Designated States: AT (European patent), BE (European patent), CH (European patent), DE (European patent),]
(22) Date de dépôt international : 2 mai 1984 (02.05.84) DK, FR (brevet européen), GB (brevet européen). JP, LU (brevet européen), NL (brevet européen), SE (brevet européen), US.(22) International filing date: May 2, 1984 (02.05.84) DK, FR (European patent), GB (European patent). JP, LU (European patent), NL (European patent), SE (European patent), US.
(31 ) Numéro de la demande prioritaire: 84786(31) Priority application number: 84786
(32) Date de priorité: 3 mai 1983 (03.05.83) Publié*(32) Priority date: May 3, 1983 (03.05.83) Issued *
Avec rapport de recherche internationale.With international search report.
(33) Pays de priorité: LU A vant l'expiration du délai prévu pour la modification des revendications, sera republiée si de telles modifications sont reçues.(33) Country of priority: LU Before the expiry of the period provided for the modification of the claims, will be republished if such modifications are received.
(71) Déposant (pour tous les Etats désignés sauf US): S. S. M. INTERNATIONAL CH EM ICAL COMPANY LIMITED [VC/VC]; Lot 18, Kingstown (VC). (88) Date de publication du rapport de recherche internationale: 14 mars 1985 (14.03.85)(71) Applicant (for all designated states except the US): S. S. M. INTERNATIONAL CH EM ICAL COMPANY LIMITED [VC / VC]; Lot 18, Kingstown (VC). (88) Date of publication of the international search report: March 14, 1985 (March 14, 85)
(71X72) Déposant et inventeur: SPEECKE, André [BE/BE] ; Route de Bastogne, 81 , B-6680 Manhay (BE).(71X72) Applicant and inventor: SPEECKE, André [BE / BE]; Route de Bastogne, 81, B-6680 Manhay (BE).
(74) Mandataires: DE BRABANTER, Maurice etc. : Bureau Vander Haeahen, Avenue de la Toison d'Or, 63, B- 1060 Bruxelles (BE).(74) Agents: DE BRABANTER, Maurice etc. : Bureau Vander Haeahen, Avenue de la Toison d'Or, 63, B- 1060 Brussels (BE).
(54) Title: COMPOSITION HAVING AN IMPROVED PHARMACEUTICAL ACTIVITY AND UTILISATION THEREOF IN VETERINARY MEDECINE(54) Title: COMPOSITION HAVING AN IMPROVED PHARMACEUTICAL ACTIVITY AND UTILIZATION THEREOF IN VETERINARY MEDICINE
(54) Titre: COMPOSITION A ACTIVITE PHARMACEUTIQUE AMELIOREE ET UTILISATION DECELLE-CI POUR DES USAGES VETERINAIRES(54) Title: COMPOSITION WITH IMPROVED PHARMACEUTICAL ACTIVITY AND USE THEREOF FOR VETERINARY USES
(57) Abstract(57) Abstract
An antibiotic composition comprising simultaneously oxytetracyclin, procain benzylpenicillin and colistin sulphate has a combined synergie activity susceptible to cure necrotic diseases and mucosa troubles for which no efficient remedy has been found heretofore.An antibiotic composition comprising simultaneously oxytetracyclin, procain benzylpenicillin and colistin sulphate has a combined synergy activity susceptible to cure necrotic diseases and mucosa troubles for which no efficient remedy has been found heretofore.
(57) Abrège(57) Abbreviation
Une composition antibiotique comprenant simultanément de l'oxytétracycline, de la procaine benzylpénicilline et du sulfate de colistine exerce une action combinée synergique susceptible de guérir les maladies nécrotiques et les affections des muqueuses pour lesquelles il n'existe pas à ce jour de remèdes valables. An antibiotic composition comprising simultaneously oxytetracycline, procaine benzylpenicillin and colistin sulfate exerts a combined synergistic action capable of curing necrotic diseases and affections of the mucous membranes for which there are no valid remedies to date.
UNIQUEMENT A TITRE D'INFORMAΗONONLY FOR INFORMATION
Codes utilises pour identifier les Etats parti es au PCT, sur les pages de couverture des brochures publiant des demandes internationales en vertu du PCT.Codes used to identify States party to the PCT, on the cover pages of brochures publishing international applications under the PCT.
AT Autriche KR République de CoréeAT Austria KR Republic of Korea
AU Australie LI LiechtensteinIN Australia LI Liechtenstein
BE Belgique LK Sri LankaBE Belgium LK Sri Lanka
BG Bulgarie LU LuxembourgBG Bulgaria LU Luxembourg
BR Brésil MC MonacoBR Brazil MC Monaco
CT République Centrafricaine MG MadagascarCT Central African Republic MG Madagascar
CG Congo MR MauritanieCG Congo MR Mauritania
CH Suisse MW MalawiCH Switzerland MW Malawi
CM Cameroun NL Pays-BasCM Cameroon NL Netherlands
DE Allemagne, République fédérale d' NO NorvègeDE Germany, Federal Republic of NO Norway
DK Danemark RO Roumanie π Finlande SD SoudanDK Denmark RO Romania π Finland SD Sudan
FR France SE SuèdeFR France SE Sweden
GA Gabon SN SénégalGA Gabon SN Senegal
GB Royaume-Uni SU Union soviétiqueGB United Kingdom SU Soviet Union
HU Hongrie TD TchadHU Hungary TD Chad
JP Japon TG TogoJP Japan TG Togo
KP Republique populaire démocratique de Corée US Etats-Unis d'Amérique KP Democratic People's Republic of Korea US United States of America

Claims

REVENDICATIONS
1, Composition antibiotique comprenant, sous une forme Injectable, un mélange synergique d'un antibiotique du type oxytetracycline et d'un antibiotique du type benzylpénicilline en vue de combattre certaines maladies dues à des bactéries, caractérisée en ce qu'elle comporte outre les deux antibiotiques susdits, également un antibiotique du type Multimycine dans un rapport pondéral oxytetracycline ; benzylpénicilline : Multimycine compris dans une plage variant de 10 à 30 , de préférence 20, du premier composé, 90 à 70, de préférence 80 du deuxième composé et 1 à 15, de préférence 7 du troisième composé.1, Antibiotic composition comprising, in an injectable form, a synergistic mixture of an antibiotic of the oxytetracycline type and of an antibiotic of the benzylpenicillin type in order to combat certain diseases due to bacteria, characterized in that it comprises, in addition to the two the above antibiotics, also an antibiotic of the Multimycin type in an oxytetracycline weight ratio; benzylpenicillin: Multimycin included in a range varying from 10 to 30, preferably 20, of the first compound, 90 to 70, preferably 80 of the second compound and 1 to 15, preferably 7 of the third compound.
2. Composition selon la revendication 1, caractérisée en ce qu'elle correspond à la formule galenique obtenue en mélangeant pour 100 ml les constituants suivants :2. Composition according to claim 1, characterized in that it corresponds to the galenical formula obtained by mixing for 100 ml the following constituents:
1/ Oxytétracycline HCl 926 mg 2/ Procaîne Benzylpénicilline 24000 mg 3/ Sulfate de colistine 10 à 100 mg 4/ Polyvidone constituant du solvant1 / Oxytetracycline HCl 926 mg 2 / Procain Benzylpenicillin 24000 mg 3 / Colistin sulfate 10 to 100 mg 4 / Polyvidone constituent of the solvent
Aqua distillata ad 1 mlAqua distillata ad 1 ml
5/ Magnes . formaldehyd bisulfis 7 mg Magnesium Oxyd um 7 mg Methylis paraoxybenzoas 0,68 mg Natri citras (Vitamine A) 3 , 5 mg Natri carboxymethyl cellulos diluant Propyli para hydroxybenzoas 0,12 mg Polyvinyl pyrrolid. diluant5 / Magnes. formaldehyd bisulfis 7 mg Magnesium Oxyd um 7 mg Methylis paraoxybenzoas 0.68 mg Natri citras (Vitamin A) 3.5 mg Natri carboxymethyl cellulos diluent Propyli para hydroxybenzoas 0.12 mg Polyvinyl pyrrolid. diluent
6/ Propyléneglycol 12 mg en tant que solvant 6 / Propylene glycol 12 mg as solvent
3. Utilisation d'une composition selon l'une des revendications 1 et 2, pour combattre les infections des muqueuses, en particulier les mycoses provoquées par des champignons, toutes les maladies nécrotiques, la péritonite, la pneumonie infectieuse et le ''blanc mal chez les bovins''. 3. Use of a composition according to one of claims 1 and 2, for combating infections of the mucous membranes, in particular mycoses caused by fungi, all necrotic diseases, peritonitis, infectious pneumonia and '' mal blanc in cattle ''.
EP84901729A 1983-05-03 1984-05-02 Composition having an improved pharmaceutical activity and utilisation thereof in veterinary medecine Withdrawn EP0150186A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
LU84786 1983-05-03
LU84786 1983-05-03

Publications (1)

Publication Number Publication Date
EP0150186A1 true EP0150186A1 (en) 1985-08-07

Family

ID=19730090

Family Applications (1)

Application Number Title Priority Date Filing Date
EP84901729A Withdrawn EP0150186A1 (en) 1983-05-03 1984-05-02 Composition having an improved pharmaceutical activity and utilisation thereof in veterinary medecine

Country Status (9)

Country Link
EP (1) EP0150186A1 (en)
JP (1) JPH01500746A (en)
CA (1) CA1221635A (en)
DK (1) DK3585D0 (en)
IE (1) IE57352B1 (en)
IT (1) IT1180166B (en)
PT (1) PT78540B (en)
WO (1) WO1984004249A2 (en)
ZA (1) ZA843277B (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE59808313D1 (en) * 1998-02-02 2003-06-12 Boehringer Ingelheim Vetmed USE OF COMBINATIONS OF ACTIVE SUBSTANCES FROM ANTIBIOTICS AND TERPENIC PLANT EXTRACTS IN ANIMAL MEDICINE
AU2008304019A1 (en) * 2007-09-25 2009-04-02 Pastoral Greenhouse Gas Research Ltd Phage Phi-mru polynucleotides and polypeptides and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE505709A (en) *
FR1602275A (en) * 1967-12-18 1970-11-02 Tetracycline derivs antibiotics
FR2364653A1 (en) * 1976-09-20 1978-04-14 Synthelabo Synergistic antibiotic mixts. - contg. colistin and benzathine benzyl penicillin

Also Published As

Publication number Publication date
IT8420759A0 (en) 1984-05-02
DK3585A (en) 1985-01-03
IT8420759A1 (en) 1985-11-02
IT1180166B (en) 1987-09-23
IE841088L (en) 1984-11-03
JPH01500746A (en) 1989-03-16
WO1984004249A2 (en) 1984-11-08
IE57352B1 (en) 1992-08-12
PT78540A (en) 1984-06-01
DK3585D0 (en) 1985-01-03
PT78540B (en) 1986-07-14
WO1984004249A3 (en) 1985-03-14
CA1221635A (en) 1987-05-12
ZA843277B (en) 1984-12-24

Similar Documents

Publication Publication Date Title
FR2914188A1 (en) Pharmaceutical composition, useful as medicine, preferably as drugs in the treatment of degenerative diseases, comprises oxime based chloestenone compounds or their esters or derivatives, and oil or its mixture
BE895724A (en) NEW THERAPEUTIC USE OF DIHYDROCYCLOSPORIN D
EP1102586B1 (en) Use of ginkgo biloba extracts for preparing a medicine for treating amyotrophic lateral sclerosis
EP0069659A1 (en) Medicine containing the reaction product of a carboxylic acid and a basic amino acid
FR2590170A1 (en) THERAPEUTIC AGENTS BASED ON ACYLOXYALCANOYLCHOLINE SALT, IMPROVING THE TREATMENT OF DEMENTIA
JPS62501360A (en) Disease treatment agents containing pharmaceutically active compounds
FR2591483A1 (en) PHARMACEUTICAL ANTIVIRAL AND ANTITUMOR COMPOSITIONS.
JP2000095683A (en) Skin lotion
WO1984004249A2 (en) Composition having an improved pharmaceutical activity and utilisation thereof in veterinary medecine
JPH0255404B2 (en)
EP0670164B1 (en) Homeopathic solutions containing a nucleic acid
EP0739629A1 (en) Associations comprising (-)hydroxycitrate and having new therapeutical activities
US7955623B2 (en) Pharmaceutical preparations for treating inflammatory diseases
JP2020183350A (en) Dentifrice
FR2520230A1 (en) MEDICAMENT PREPARATIONS CONTAINING A TETRAIODOTHYRO CARBOXYLIC ACID DERIVATIVE, IN PARTICULAR FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA
EP0919239A1 (en) Pharmaceutical composition for the treatment of acute gastroenteritis comprising a rehydration solution.and a compound with synergistic action
FR2515516A1 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF INFECTED RENAL LITHIASIS CONTAINING PROPIONOHYDROXAMIC ACID OR ITS PHARMACY ACCEPTABLE SALTS
CH678275A5 (en)
FR2747307A1 (en) Use of ceramide(s), preferably with added magnesium and vitamin E
WO2022097042A1 (en) Novel therapeutic composition based on essential oils at low doses
FR2607006A1 (en) Pharmaceutical composition based on Euphorbia pilulifera and/or hirta, used, in particular, as an intestinal disinfectant and/or cicatrising agent
CA1179943A (en) Process for obtaining novel pharmaceutical compositions with analgesic properties
FR2572934A1 (en) WATER-SOLUBLE PHARMACEUTICAL COMPOSITIONS BASED ON (-) CIS-1,2-EPOXYPROPYLPHOSPHONIC ACID SALTS WITH AMINO ACIDS
EP0214947A1 (en) Antalgic and anti-inflammatory composition for the treatment of arthrosis
BE888521A (en) ANTIEMETIC COMPOSITIONS BASED ON GALPHAMETHYLPREDNISCOLONE DERIVATIVES AND THEIR USE

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19841231

AK Designated contracting states

Designated state(s): AT BE CH DE FR GB LI LU NL SE

17Q First examination report despatched

Effective date: 19870320

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19871202

RIN1 Information on inventor provided before grant (corrected)

Inventor name: SPEECKE, ANDRE